long intergenic non-protein coding RNA 2132Genealiases: []
Q-omics provides the consensus-scored LINC02132 profile across patient tissues and cancer cell-line models. LINC02132 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC02132 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, LINC02132 RNA expression shows 10,546 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, KIRC, and THYM as cancer lineages where LINC02132 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02132 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02132 survival associations across molecular data types. LINC02132 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02132 RNA expression–survival associations across cancer types. High LINC02132 expression shows unfavorable associations in LAML, but favorable associations in SKCM, LUAD, BRCA, STAD and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC02132 RNA expression.
This table summarizes LINC02132 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02132. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02132 shows lower tumor expression in KICH, COAD, LUSC, THCA and LUAD and higher tumor expression in KIRC. The KIRC box plot shows higher LINC02132 RNA expression in tumor versus normal tissue (log2 FC = +0.216, t-test p < 0.001).
This table shows molecular features associated with LINC02132 in patient tissues and cancer cell lines. In patient samples, LINC02132 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
